このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Gencurix マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Sung-Rai Cho

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

更新なし

Recent updates

Gencurix (KOSDAQ:229000) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 28

CEO（最高経営責任者

Sung-Rai Cho

no data

在職期間

Sung-Rai Cho serves as Chief Executive Officer of Gencurix Inc.

Gencurix マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Recent updates

Second quarter 2024 earnings released: ₩281 loss per share (vs ₩506 loss in 2Q 2023)

New minor risk - Share price stability

Gencurix Inc. announced that it has received KRW 2 billion in funding

New major risk - Financial position

J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion.

J&L Agent Co., Ltd. and other agreed to acquire 9.9% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 5.9 million.

Full year 2023 earnings released: ₩1,629 loss per share (vs ₩2,989 loss in FY 2022)

Gencurix Inc. announced that it has received KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.

Gencurix Inc. announced that it expects to receive KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.

Gencurix Inc. announced that it expects to receive KRW 3.99999552 billion in funding

Gencurix Inc. Obtains Approval for Companion Diagnostic of Digital Pcr-Based Egfr Mutation Test

Gencurix Announces Korean and Japanese Cancer Patients' 15-Year Follow-Up Prognostic Test Clinical Results

Investor sentiment improved over the past week

Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

Gencurix Inc. announced that it expects to receive KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gencurix (KOSDAQ:229000) Is Posting Healthy Earnings, But It Is Not All Good News

New 90-day high: ₩21,700

New 90-day high: ₩21,000

New 90-day low: ₩16,950

Gencurix Inc. announced that it has received KRW 2 billion in funding

Gencurix Inc. (KOSDAQ:A229000) agreed to acquire a 41% stake in Nano Bio Life Co., Ltd. from Soo-kyung Kim, Jihye Cheon, Injoong Kim, Ki-moon Song, Jichul Hyun and Sujin Lee for KRW 3.7 billion.

New 90-day high - ₩26,750

New 90-day low - ₩15,700

CEO（最高経営責任者

在職期間

Gencurix マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Recent updates

Second quarter 2024 earnings released: ₩281 loss per share (vs ₩506 loss in 2Q 2023)

New minor risk - Share price stability

Gencurix Inc. announced that it has received KRW 2 billion in funding

New major risk - Financial position

J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion.

J&L Agent Co., Ltd. and other agreed to acquire 9.9% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 5.9 million.

Full year 2023 earnings released: ₩1,629 loss per share (vs ₩2,989 loss in FY 2022)

Gencurix Inc. announced that it has received KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.

Gencurix Inc. announced that it expects to receive KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.

Gencurix Inc. announced that it expects to receive KRW 3.99999552 billion in funding

Gencurix Inc. Obtains Approval for Companion Diagnostic of Digital Pcr-Based Egfr Mutation Test

Gencurix Announces Korean and Japanese Cancer Patients' 15-Year Follow-Up Prognostic Test Clinical Results

Investor sentiment improved over the past week

Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

Gencurix Inc. announced that it expects to receive KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gencurix (KOSDAQ:229000) Is Posting Healthy Earnings, But It Is Not All Good News

New 90-day high: ₩21,700

New 90-day high: ₩21,000

New 90-day low: ₩16,950

Gencurix Inc. announced that it has received KRW 2 billion in funding

Gencurix Inc. (KOSDAQ:A229000) agreed to acquire a 41% stake in Nano Bio Life Co., Ltd. from Soo-kyung Kim, Jihye Cheon, Injoong Kim, Ki-moon Song, Jichul Hyun and Sujin Lee for KRW 3.7 billion.

New 90-day high - ₩26,750

New 90-day low - ₩15,700

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04